Summary & Overview
HCPCS Q0238: Tocilizumab-aazg Injection for Hospitalized COVID-19 Patients, per mg
HCPCS Level II code Q0238 represents the per-milligram billing unit for injection of tocilizumab-aazg, indicated for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). This biologic therapy code is important nationally due to its use in critical care settings and implications for hospital drug spending, utilization tracking, and inpatient therapeutic protocols.
Key payers included in the coverage discussion are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for use of tocilizumab-aazg in severe COVID-19, the typical inpatient service setting where the code is billed, and the billing unit definition (1 mg). The publication also covers benchmarks and payer policy alignment, common documentation points relevant to billing, and related coding considerations where available.
This analysis provides practitioners, revenue cycle staff, and policy stakeholders with actionable context on how HCPCS Level II code Q0238 fits into inpatient COVID-19 treatment pathways, and what aspects of coverage and billing practice to review when managing claims and utilization for this therapy. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code Q0238 describes an injection of tocilizumab-aazg for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The code is reported per 1 mg of the product.
Service Type: Therapeutic drug administration (intravenous biologic therapy) for hospitalized COVID-19 patients
Typical Site of Service: Inpatient hospital setting, including intensive care units and other acute care units where patients receive supplemental oxygen, non-invasive or invasive ventilation, or ECMO.
Clinical & Coding Specifications
Clinical Context
A hospitalized adult with severe COVID-19 pneumonia receiving systemic corticosteroids develops escalating oxygen needs, requiring high-flow nasal cannula, non-invasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The clinical workflow begins with inpatient assessment by the hospitalist or intensivist, confirmation of active SARS-CoV-2 infection and hypoxemic respiratory failure, review of contraindications (e.g., active serious infections, elevated liver enzymes, known hypersensitivity), and verification that the patient is receiving systemic corticosteroids. After multidisciplinary discussion and documentation of indications, the pharmacy prepares tocilizumab-aazg for intravenous infusion. The medication is administered by registered nursing staff in the intensive care unit or an acute care inpatient bed with monitoring for infusion reactions, hemodynamic status, and laboratory parameters. Post-administration, clinicians monitor for clinical response (reduced oxygen requirement, improved ventilator parameters) and adverse events (secondary infection, neutropenia, transaminitis). Billing for the administered product uses HCPCS code Q0238 with dosing recorded in milligrams and exact units billed per 1 mg increments.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day |